Kornimate/medical-research-clean huggingface dataset:
covid-19 and lung ultrasound utility

Conditions: Covid19; Lung Infection

Summary: ultrasounds are usually done by a specially trained health professional in the hospital or emergency department (ed) setting. using a novel single-probe device, the ultrasound can be plugged into an ios / android device. the purpose of this research is to assess the usefulness of lung ultrasound imaging, performed by the patient in the home setting for the management of the covid-19 disease using this novel highly-portable ultrasound.

this will be a prospective self-controlled design. the study subjects will receive a telehealth visit from a healthcare provider (hcp) to assess for any change in their covid-19 symptoms. the hcp will recommend the patient remain at home, or to go to an emergency department based on standard of care and clinical decision making. subsequently, the study subjects will receive a teleguidance session with a radiologist who is trained in lung ultrasound (lus) in order to obtain images of their chest. the physician performing lus remotely will report lus findings in a standard quality assurance (qa) document, including image quality, interpretation, and recommendations. this qa report will be study data and not shared with the patient. the two providers will be blinded, except when there is a disagreement between the telemed lus and clinical interview. the study staff will determine when this disagreement occurs. they will notify the study investigators and radiologist, who will then discuss and come to an agreement within 24 hours. if deemed concerning, they will then contact the hcp and unblind them as to the radiographic findings. there will be no delay in medical care advised by the subject's hcp. specifically, the nurse will inform the hcp by a phone call that the physician performing lus remotely found a significant change in lus findings. the hcp will then be given access to the lus report (as well as images if desired), and will review the decision to seek medical care with the telemed doctor.

Eligibility criteria:
inclusion criteria: * must be 18 years or older and able to provide a valid informed consent. * must have a nasal swab positive rt-pcr for covid-19 * must have access to wi-fi at home exclusion criteria: * subjects unwilling or unable to directly provide consent. * the following vulnerable study subject populations will not be eligible: prisoners, mentally impaired, or disadvantaged groups. * any condition deemed by the principal investigator, in his or her judgment, that may impact the subject's ability to meet the requirements necessary to collect the exam data required.
oral health assessment of children in cp class

Conditions: Dental Caries

Summary: few oral exams are performed on 6-year-olds (key age for carious disease). this project aims to increase the number of oral check-ups for 6-year-olds in fragile areas (rep/rep+ areas).


Eligibility criteria:
inclusion criteria: * be a first-grade student enrolled in a school in a zone rep/rep+ * have a parental permission * good understanding of the french language exclusion criteria: - lack of parental permission

Keywords: oral hygiene public health children prevention
a study to evaluate ketamine for the treatment of rett syndrome

Conditions: Rett Syndrome

Summary: this 2 cohort, sequential, ascending dose study will assess the safety, tolerability and efficacy of oral ketamine dosed in a single 5-day bid regimen in addition to placebo, in a 4-week cross-over design in patients with rett syndrome. approximately 12 patients per cohort are anticipated to participate for approximately 8-10 weeks at approximately 7 us study centers.

this study is designed to assess oral ketamine for the treatment of rett syndrome and consists of up to 4 ascending dose cohorts, each assessing 1 dose level of ketamine vs placebo. patients will receive in either order, a 5-day bid regimen of both placebo and the cohort-specified dose level of oral ketamine. patients may only participate in 1 cohort. safety and tolerability will be assessed via patient disposition, vital signs, physical examination, adverse events and concomitant medication use. efficacy will be assessed via physician and caregiver questionnaires and assessments, and continuous, wearable, at-home biosensor data collection. an independent safety committee will review safety data from each cohort to determine if the subsequent ascending dose cohort is warranted. a total of 12 patients per cohort is anticipated at approximately 7 sites. the screening period will last between 2 and 4 weeks, the cross-over treatment period will last 4 weeks, and the safety follow-up period will last 2 weeks. total patient participation is approximately 8-10 weeks.

Eligibility criteria:
inclusion criteria: * female rett syndrome patients diagnosed with rett syndrome with a confirmed mecp2 mutation * between the ages of 6 and 12, inclusive, who have not achieved menarche * ability to take oral medications * are generally healthy. exclusion criteria: * patients not on stable medication regimens/other types of behavioral, educational, or dietary interventions for at least 4 weeks, * are taking medications that may interact with ketamine, * have a condition where increased blood pressure, spinal fluid pressure, or ocular pressure may put the patient at increased risk.

Keywords: mecp2 rtt retts ketamine
multimodality imaging assessment of the severity of mitral regurgitation

Conditions: Mitral Regurgitation

Summary: to investigate to assess the severity of mitral regurgitation by multimodality imaging.

in the single-center and open-label study, the researcher will compare the changes of ultrasonic cardiography (ucg) parameters when patients in fasting, anaesthesia and rehydration firstly. the aims are to clarify the effect of fasting and anaesthesia on the assessment of mitral regurgitation (mr) severity and the corrective effect of intravenous rehydration. the researcher then will investigate the correlation and consistency of multimodality imaging in assessing the severity of mitral regurgitation. the aim is to acquire more accurate, objective and reproducible parameters, to provide new solution for the precise assessment of mr severity and to guide the selection of clinical treatment and timing.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old 2. all-caused moderate or severe mr assessed by trans-thoracic echocardiography (tte) : 1) eroa ≥0.3cm\^2; 2) rvol ≥45ml 3. the patient has signed an informed consent form. exclusion criteria: 1. unstable angina, acute myocardial infarction and surgical history of coronary artery bypass grafting (cabg) and percutaneous coronary intervention (pci) within 3 months before recruit 2. acute heart failure or acute worsening of chronic heart failure requiring vasoactive drug therapy 3. severe infections, septicaemia 4. severe hepatic insufficiency ( child-pugh class c) 5. severe renal insufficiency ( chronic kidney disease (ckd) stage 5: estimated glomerular filtration rate (egfr) \<15ml/min or dialysis) 6. hypotensive state, shock ( systolic blood pressure \<90mmhg or mean arterial pressure \<70mmhg with tissue hypoperfusion and urine output \<30ml/h) 7. uncontrolled diseases of the haematological system: acute gastrointestinal bleeding, intracranial haemorrhage or haemorrhage from other organs, acute pulmonary embolism or deep vein thrombosis, congenital or acquired haemorrhagic disease such as haemophilia, anaphylactic purpura and acute leukaemia, severe abnormalities in haematological parameters such as platelet count \ 3 8. contraindication for trans-esophageal echocardiography (tee) such as oesophageal constriction, oesophageal tumour, oesophageal fistula, oesophageal varices, cervical vertebral instability 9. contraindication for cmr such as metal foreign matter in the body, claustrophobia 10. contraindication for intravenous anaesthesia such as allergy to anaesthetics 11. pregnancy or breastfeeding 12. the patient does not sign an informed consent form. 13. due to other reasons the patient is not suitable for enrollment assessed by the researcher.

Keywords: mitral regurgitation ultrasonic cardiography cardiac magnetic resonance
a study of the efficacy and safety of ulipristal acetate intermittent treatment for abnormal uterine bleeding associated with leiomyomas

Conditions: Leiomyoma; Uterine Hemorrhage

Summary: this study will evaluate the superiority of ulipristal acetate versus placebo for the treatment of abnormal uterine bleeding associated with uterine fibroids


Eligibility criteria:
inclusion criteria: * premenopausal women, 18-50 years, inclusive. * cyclic abnormal uterine bleeding (heavy or prolonged). * menstrual blood loss (mbl) of ≥ 80 ml as measured by the alkaline hematin method in the first 8 days of menses. * minimum of one discrete leiomyoma observable by transvaginal ultrasound. * endometrial biopsy without evidence of malignancy or atypical or non-atypical hyperplasia. exclusion criteria: * history of uterine surgery that would interfere with the study endpoints. * known coagulation disorder including bleeding disorder or clotting disorder. * history of, or current uterine, cervix, ovarian, or breast cancer. * alanine transaminase (alt), aspartate transaminase (ast), alkaline phosphatase (alp), or total bilirubin two times or greater than the upper limit of normal range.
multivariate analysis of serum high sensitivity c-reactive protein in patients with acute phase stroke

Conditions: Stroke; National Institutes of Health Stroke Scale; Serum High Sensitivity C-Reactive Protein

Summary: stroke is one of main causes of death and impairment worldwide. objective of this study is to analyze serum high sensitivity c-reactive protein in acute phase stroke in patients attended at petróleos mexicanos hospital central sur de alta especialidad and to correlate with stroke extension and clinical features.


Eligibility criteria:
inclusion criteria: * patients suspected of acute phase stroke who arrive to emergency room at our hospital * patients affiliated to petróleos mexicanos medical system * patients of any gender * patients between 18 and 80 years old exclusion criteria: * stroke provoked by angiographic procedure * pregnancy * patient under chemotherapy or radiotherapy * recently surgery or trauma among last 30 days * heparin usage * stroke and/ or thrombolysis history * active infection * liver disease

Keywords: stroke national institutes of health stroke scale serum high sensitivity c-reactive protein
longitudinal observational study for middle term follow-up patients admitted for acute dyspnea in tunisia

Conditions: Longitudinal Observational Study With 6 Months Follow-up

Summary: the purpose of the sidi study is to follow, few months after discharge from the hospital, the patients admitted to the 3 emergency departments in tunisia for acute dyspnea and to determine the proportion and the factors favoring rehospitalization and death.


Eligibility criteria:
inclusion criteria: * patients admitted for unexpected respiratory difficulty * patient admitted to the emergency department * one of the following 3 criteria have to be present at admission to the er: * o2 \< or = 95% * respiratory rate rr \> or = 20 * suffocation sensation exclusion criteria: * patients \ 85 years' old * pregnancy * history of allergic asthma at early age * diagnosis retained of pulmonary embolism * patients with heart failure (hf) with left ventricular ejection fraction lvef \<40% are known beforehand or discovered at admission to er * known allergy for polyamide; polyester; elastane; silicone; silver; synthetic material cardiorespiratory disorders which may be aggravated by the slight compression of the thorax open wound on the skin, at the level of the trunk
dose-finding study of khk7791 in hyperphosphatemia patients

Conditions: Hyperphosphatemia

Summary: to evaluate the effect and safety of khk7791 to treat hyperphosphatemia in ptatients on hd.


Eligibility criteria:
inclusion criteria: * patients with stable chronic renal failure who have undergone hemodialysis three times per week for at least 12 weeks until screening examination. * dialysis conditions (dialysate, dialyzer, frequency of dialysis per week, dialysis duration, blood flow rate, and dialysate and substitution fluid flow rates), excluding dry weight, should have been unchanged during the last 2 weeks before screening examination. * taking phosphate binders three times per day. the prescribed drug and dosage regimen should have been unchanged during the last 4 weeks before screening examination. * serum phosphorus levels should be in the range of ≥3.5 and ≤6.0 mg/dl at screening examination. * if on any vitamin d or calcimimetics regimen, then the prescribed drug and dosage regimen should have been unchanged for the last 4 weeks before screening examination. exclusion criteria: * ipth \>600 pg/ml (should be based on the most recent value from the patients' medical records, etc. before pre-enrollment) * having concurrent or a history of inflammatory bowel disease (ibd) or diarrhea-predominant irritable bowel syndrome * history of gastrectomy or enterectomy (excluding endoscopic resection and cecectomy) or having undergone gastrointestinal tract surgery within 3 months before screening examination. * having concurrent severe heart disease \[including congestive heart failure, defined as new york heart association (nyha) cardiac functional classification of class iii or iv, and cardiovascular disease requiring hospitalization, such as myocardial infarction\] or hepatic impairment (including ast/alt ≥100 u/l at screening examination, or cirrhosis). * developed cerebrovascular disease (such as cerebral infarction and hemorrhage) or cardiovascular disease (such as myocardial infarction and unstable angina) requiring hospitalization within 6 months before screening examination. * uncontrollable hypertension or diabetes. * scheduled for living donor kidney transplant, change in the mode of dialysis, home hemodialysis, or change in the dialysis center (relocate to another hospital/clinic) during the study period. * any diagnosis of and treatment of malignancy within 5 years before screening examination (excluding basal cell carcinoma or surgically resected intraepithelial carcinoma of uterine cervix).

Keywords: tenapanor hyperphosphatemia hemodialysis
"treatment of active hbv with γδt cells" clinical trial protocol

Conditions: Adoptive Treatment for Hepatitis B With γδT Cells

Summary: to evaluate the safety and anti-hbv efficacy of γδt cells.

in this clinical trial, we will thoroughly evaluate the safety of in vitro expanded γδt cells, including allogeneic originated γδt cells, in clinical treatment of active hbv. at the same time, we will carefully and thoroughly examine and evaluate the clinical efficacy of γδt cells against active hbv, including lowering speed of dna copy number, and the transferring rate of hbeag from positive to negative.

Eligibility criteria:
inclusion criteria: * 1. aged 18-45 years old, male or female; 2. informed consent; 3. patient who were tested hbsag and hbeag positive; 4. hbv dna loads\>1 million copy/ml;5. liver function test alanine aminotransferase (alt) 160 iu/l≤400 iu/l; 6. no jaundice, total bilirubin is normal;7. for patients with new onset, oral antiviral drugs limited for sebivo. exclusion criteria: * 1. pregnant women;2. patients complicated with other viruses, bacteria infections and other infectious diseases;3. with other diseases such as diabetes, cancer, hypertension, coronary heart disease, endocrine system disease, mental illness, neurological disease, vascular circulation system diseases and so on, and after clinical doctors diagnose, evaluate the immune cells are not suitable for treatment of patients;4. there is no immediate relatives, immediate family members suffering from infectious diseases including e antigen positive, or immediate family is not suitable for patients as white blood cells supplier;5. other indications that is not suitable for the treatment

Keywords: hbv infection,γδt cells,adoptive treatment
french observatory of acute heart failure-2

Conditions: Heart Failure

Summary: in 2009, ofica 1 provided a snapshot of the management of acute heart failure in france. over the past 10 years, practitioners have observed a change in the profiles of hospitalized patients and it is necessary to specify the evolution of these characteristics, especially since the recommendations concerning management have changed significantly; this is the objective of this observatory. like patients suffering from chronic diseases such as diabetes or asthma, heart failure patients are therefore at the center of their management. compliance is improved when patients have understood the reason for the prescription. ideally, compliance should not be achieved by respecting externally imposed norms, but rather by respecting norms that are understood, adapted, personalized and accepted. a self-questionnaire will thus be given to patients on the day of inclusion in the study. in heart failure patients with an average age of 80 years, systematic screening for cognitive disorders using a simple test recommended by the french national authority for health (haute autorité de santé), the codex test, will make it possible to offer more appropriate care if necessary (geriatric or neurology consultation). finally, follow-up at 3 months and at 1 and 2 years will be carried out by matching with data from the national health data system (snds)


Eligibility criteria:
inclusion criteria: * patient hospitalized, regardless of the initial mode of admission, with acute heart failure (de novo heart failure or decompensation of chronic heart failure) of any severity and corresponding to one of the following clinical situations : 1. pulmonary edema, hypertensive or not 2. congestive heart failure (pulmonary congestion, peripheral oedema) 3. cardiogenic shock 4. high output heart failure 5. isolated right heart failure * patient who agreed to participate in the study exclusion criteria: * expressed refusal to participate in the study * scheduled hospitalization for assessment * surgical context (immediate postoperative period) * diagnosis of acute heart failure reversed to another diagnosis before end of hospitalization
italian network mds registry

Conditions: Myelodysplastic-Myeloproliferative Diseases

Summary: epidemiological data collection of adult patients affected by myelodysplastic syndrome (mds) newly diagnosed.

development of an italian regional registries mds network using the same electronic case report form for data storage, with the following broad aims: * ability to aggregate and process anonymous epidemiological data collected by individual regional registers; * ability to aggregate the available data with those of other international registries existing.

Eligibility criteria:
inclusion criteria: * new diagnosis of mds exclusion criteria: * patient who refuse the signature of informed consent

Keywords: mds myelodisplastic syndrome
clinical study of rhtpo in hematopoietic stem cell mobilization for autologous transplantation in acute leukemia

Conditions: Hematopoietic Stem Cell Mobilization

Summary: evaluation of the efficacy and safety of recombinant human thrombopoietin (rhtpo) at 300 u/kg/day for hematopoietic stem cell mobilization in autologous transplantation among acute leukemia patients


Eligibility criteria:
inclusion criteria: 1. age 18～65 years, regardless of gender. 2. histopathologically confirmed acute leukemia with immunohistochemical validation 3. sustained complete hematologic remission with documented minimal residual disease (mrd) negativity. 4. eastern cooperative oncology group (ecog) performance status smaller than 2 and a life expectancy of more than 6 months 5. no active infectious disease; no severe organ failure. 6. willingness to participate with written informed consent for study enrollment. exclusion criteria: 1. liver dysfunction (alanine aminotransferase or bilirubin greater than two times the normal upper limit). 2. renal dysfunction (creatinine or urea higher than 1.5 times the normal upper limit). 3. any disease that could put patients at high risk, including but not limited to unstable cardiac disease, uncontrolled atrial fibrillation or hypertension, severe diabetic retinopathy 4. rhtpo aller- gies. 5. severe prior thrombosis-event. 6. history of other malignancy, unless cured for more than 3 years 7. pregnant or lactating women 8. severe infectious disease (uncured tuberculosis, pulmonary aspergillosis) 9. epilepsia, dementia or any mental disease requiring treatment. 10. other conditions deemed inappropriate for study participation by the investigator.

Keywords: recombinant human thrombopoietin
early identification of children with asthma

Conditions: Asthma in Children

Summary: gps are one of the key players in the early diagnosis of chronic diseases, such as asthma in pre-school children, by detecting symptoms of illness as early as possible. patient health data is collected on an ongoing basis in gps' electronic medical records, but remains little exploited despite its potential. helping gps to identify asthma in pre-school children, based on the information in their electronic medical records, could help them to diagnose the condition early and thereby reduce the morbidity and mortality associated with it. an algorithm developed and evaluated in a primary care data warehouse should help gps to identify children with a diagnosis of asthma at an early stage.

asthma is the most common chronic disease affecting children. it is defined by repeated episodes of heterogeneous respiratory symptoms, such as wheezing, breathlessness, chest tightness and cough, which vary in time and intensity, as well as variable expiratory flow limitation. asthma in pre-school children corresponds to asthma in children under the age of 6. diagnosis in children is particularly complex, due to the difficulty of performing respiratory tests such as spirometry, and the fact that symptoms often diminish with age. diagnosis is based on a number of factors, including response to treatment and the absence of a differential diagnosis. although asthma in pre-school children is frequent and sometimes serious, it is under-diagnosed and not optimally treated. gps are among the key players in the early diagnosis of chronic diseases, by detecting symptoms of illness as early as possible. patient health data is collected on an ongoing basis in gps' electronic medical records, but remains little exploited despite its potential. helping gps to identify asthma in pre-school children, based on the information in their electronic medical records, could help them to diagnose the condition at an early stage, thereby reducing the morbidity and mortality associated with it. an algorithm, developed and evaluated in a primary care data warehouse, should help gps to identify children with a diagnosis of asthma at an early stage.

Eligibility criteria:
inclusion criteria: * children aged 2 years 0 days to 5 years 11 months and 30 days inclusive * consultation in one of the 4 maisons de santé pluriprofessionnelle connected to the primege normandie primary care data warehouse: neufchâtel-en-bray, val-de-reuil, le grand-quevilly and rouen carmes. * at least two consultations between the ages of 2 and 5, with a general practitioner in the same care setting * parents having been informed of the use of data from electronic medical records and having expressed no objection to the use of this data exclusion criteria: * children under 2 years of age * children aged 6 years 0 days and over * recourse by a patient's legal representative to one of the rgpd rights restricting the use of their data in the context of research

Keywords: predictive algorithm